one hundred seventy-nine patients with acute nonlymphoblastic leukemia in first remission ( n = 75 ) , chronic myelocytic leukemia in chronic or accelerated phase ( n = 48 ) or leukemia in advanced stage ( n = 56 ) were given hla-identical marrow grafts and randomized to receive methotrexate or cyclosporine for prevention of graft-v-host disease ( gvhd ) .
C0023418
advanced stage
C0025677
methotrexate